PRDX1 promotes clear cell renal cell carcinoma progression by modulating EGFR-dependent AKT pathway activation

Background: Renal cell carcinoma (RCC) is a highly heterogeneous malignant tumor, characterized by a globally increasing incidence and mortality rate. Although surgical resection serves as the standard treatment for localized RCC, recurrence and metastasis remain major clinical challenges. Based on patient sample analysis and signaling pathway investigation, the present study identifies peroxiredoxin 1 (PRDX1) as a potential therapeutic target for RCC. Methods: effects of PRDX1. Results: , as well as the oncogenic functions enhanced by increasing PRDX1 was blocked by gefitinib, a specific inhibitor of EGFR. Treatment with PRDX1 inhibitor showed that PRDX1 inhibition restrain the growth and metastasis of ccRCC. Conclusion: In summary, the findings of this study revealed a novel role of PRDX1 in triggering ccRCC progression by inducing the phosphorylation of EGFR, supporting that PRDX1 may serve as a potential therapeutic target for the clinical management of ccRCC.